Rumours that the US financial regulator is planning to block Amgen’s $28 billion takeover of Horizon Therapeutics have turned out to be true, and the industry is now scram
Shares in Horizon Therapeutics have been in sharp decline after reports emerged that the US financial regulator is preparing a challenge to its $28 billion takeover by Amg
Amgen has won a crunch appeals court ruling that delays generic competition to its big-selling psoriasis drug Otezla in the US until 2028, although it missed out on gettin
On the face of it, the battle between Amgen and Sanofi/Regeneron being heard in the US Supreme Court is a mundane biopharma contest over rights and royalties on PCSK9 inhi
Novartis' soon-to-be-divested Sandoz unit has filed its proposed biosimilar of Amgen's osteoporosis therapy Prolia/Xgeva with the FDA, saying it is "among the first" to fi
AbbVie's cash-cow immunology product Humira has its first biosimilar competition in the US market with the launch of Amgen's copycat product Amjevita, several years after